Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Idorsia Ltd.

Latest From Idorsia Ltd.

Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?

CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.

Approvals Cardiovascular

EMA Decision Time For Aztreonam-Avibactam; High-Stakes Meeting For Lecanamab

The European Medicines Agency is this week deciding whether a number of new drugs should win EU approval.

Europe Approvals

Idorsia Asset Sell Off Continues But Future Still Up In The Air

A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.

Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023

With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.

Business Strategies Companies
See All

Company Information